Evidence mapPaperPMID 40715910Full record

ReviewMedical oncology (Northwood, London, England)2025

The emerging role of miR-362 in cancer: expression and function across different cancer types.

Shahad Mohammed Dhiaa Younis, Abdulkareem Shareef, Lalji Baldaniya, Rami Oweis, S Renuka Jyothi, Udaybir Singh, Samir Sahoo, Ashish Singh Chauhan, Hayder Naji Sameer, Ahmed Yaseen and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shahad Mohammed Dhiaa YounisCollege of Pharmacy, Alnoor University, Mosul, Iraq. mohammedshahad396@gmail.com.
Abdulkareem ShareefAhl Al Bayt University, Karbala, Iraq.
Lalji BaldaniyaMarwadi University Research Center, Department of Pharmaceutical Sciences, Faculty of Health Sciences, Marwadi University, Rajkot, Gujarat, India.
Rami OweisOn sabbatical leave, from Jordan University of Science and Technology, Irbid, Jordan.
S Renuka JyothiDepartment of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
Udaybir SinghCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India.
Samir SahooDepartment of General Medicine, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, 751003, India.
Ashish Singh ChauhanUttaranchal Institute of Pharmaceutical Sciences, Division of Research and Innovation, Uttaranchal University, Dehradun, Uttarakhand, India.
Hayder Naji SameerCollage of Pharmacy, National University of Science and Technology, Nasiriyah, Dhi Qar, 64001, Iraq.
Ahmed YaseenGilgamesh Ahliya University, Baghdad, Iraq.
Zainab H AthabDepartment of Pharmacy, Al-Zahrawi University College, Karbala, Iraq.
Mohaned AdilPharmacy College, Al-Farahidi University, Baghdad, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) are essential post-transcriptional regulators of gene expression involved in a broad range of biological activities. Recent studies have increasingly highlighted their significant role in the development and progression of various human cancers. Among these, miR-362 has emerged as a context-dependent molecule, exhibiting both oncogenic and tumor-suppressive functions across different malignancies. Elevated levels of miR-362 have been associated to tumor-promoting effects in several cancers. In contrast, its downregulation in some other carcinoma is associated with disease progression, suggesting a tumor-suppressive role. These opposing functions underscore miR-362 involvement in complex regulatory networks and supports its potential as a biomarker for diagnosis, prognosis, and possibly therapeutic intervention. This review aims to provide an overview of the current understanding of miR-362 expression patterns, molecular targets, regulatory mechanisms, and its dual role in cancer biology, with the goal of clarifying its clinical significance in cancer diagnosis, prognosis, and therapy.

Indexed as

Gene Expression Regulation, NeoplasticMicroRNAsNeoplasmsBiomarkers, TumorHumansPrognosisBiomarkers, TumorMicroRNAsBiomarkerCancermicroRNAMir-362Molecular mechanism

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.